Promising combo aims to boost survival in liver-metastatic colorectal cancer
NCT ID NCT06280495
First seen Apr 22, 2026 · Last updated May 09, 2026 · Updated 4 times
Summary
This study tests whether adding two drugs (serplulimab and bevacizumab) to standard chemotherapy can improve outcomes for people with colorectal cancer that has spread to the liver and can be surgically removed. About 156 adults with a specific genetic type (RAS/BRAF wild-type, pMMR/MSS) will be randomly assigned to receive either the combination or chemo alone before surgery. The main goal is to see if the combination helps people live longer without the cancer growing back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.